



## Transforming growth factor beta 1 signaling is altered in the spinal cord and muscle of amyotrophic lateral sclerosis mice and patients



Marco Meroni<sup>a</sup>, Valeria Crippa<sup>a</sup>, Riccardo Cristofani<sup>a</sup>, Paola Rusmini<sup>a,b</sup>,  
 Maria Elena Cicardi<sup>a</sup>, Elio Messi<sup>a</sup>, Margherita Piccolella<sup>a</sup>, Barbara Tedesco<sup>a</sup>,  
 Veronica Ferrari<sup>a</sup>, Gianni Sorarù<sup>c</sup>, Maria Pennuto<sup>d,e,f</sup>, Angelo Poletti<sup>a,b,\*,1</sup>,  
 Mariarita Galbiati<sup>a,b,\*,1</sup>

<sup>a</sup> Dipartimento di Scienze Farmacologiche e Biomolecolari (DiSFeB), Centro di Eccellenza sulle Malattie Neurodegenerative, Università degli Studi di Milano, Milano, Italy

<sup>b</sup> Centro InterUniversitario sulle Malattie Neurodegenerative, Università degli Studi di Firenze, Roma Tor Vergata and Milano, Italy

<sup>c</sup> Department of Neurosciences, Neuromuscular Center, University of Padova, Padova, Italy

<sup>d</sup> Dulbecco Telethon Institute, Centre for Integrative Biology (CIBIO), University of Trento, Povo (TN), Italy

<sup>e</sup> Department of Biomedical Sciences, University of Padova, Padova, Italy

<sup>f</sup> Padova Neuroscience Center, Padova, Italy

### ARTICLE INFO

#### Article history:

Received 31 July 2018

Received in revised form 5 April 2019

Accepted 4 July 2019

Available online 10 July 2019

#### Keywords:

ALS  
 Muscle  
 Spinal cord  
 TGFB1  
 SMAD  
 Pax7  
 Col1a1  
 Fibronectin

### ABSTRACT

Gender differences characterize amyotrophic lateral sclerosis (ALS). Because ALS patients have increased circulating levels of transforming growth factor beta 1 (TGFB1), here we analyzed gender and disease progression–related modification of TGFB1 and its related signaling molecules in the spinal cord and skeletal muscle of ALS mice and in muscle biopsies from sporadic ALS patients. At presymptomatic stage, *Tgfb1* mRNA expression is reduced in the mouse spinal cord but is increased selectively in the male skeletal muscle. At symptomatic stage, it is induced both in the mouse spinal cord and muscle, as well as in the muscle of ALS patients. *Tgfb1* levels are induced only in the mouse spinal cord. *Smad2* and *Smad4* mRNAs are decreased in the mouse spinal cord and muscle, but SMAD2 protein levels are augmented selectively in the male mouse muscle. *Smad3* mRNA and SMAD3 protein are increased in the mouse muscle. The expression of genes controlled by TGFB1 in the muscle (*Pax7*, *Collagen1a1*, and *Fibronectin*) are reduced both in male and female ALS mice at symptomatic stage. Thus, TGFB1 modulation may serve as a novel therapeutic target for ALS.

© 2019 Elsevier Inc. All rights reserved.

### 1. Introduction

ALS is an adult-onset progressive neurodegenerative disease affecting motoneurons in the brain and spinal cord, leading to paralysis. ALS is clinically heterogeneous in age and site of disease onset, as well as in the rate of progression. ALS is mainly sporadic (sALS), with familial forms (fALS) representing 10%–15% of ALS cases.

\* Corresponding author at: Dipartimento di Scienze Farmacologiche e Biomolecolari (DiSFeB), Università degli Studi di Milano, Via Balzaretti 9, 20133 Milano, Italy. Tel.: +390250318237; fax: +390250318204.

\*\* Corresponding author at: Dipartimento di Scienze Farmacologiche e Biomolecolari (DiSFeB), Università degli Studi di Milano, Via Balzaretti 9, 20133 Milano, Italy. Tel.: +390250318215; fax: +390250318204.

E-mail addresses: [angelo.poletti@unimi.it](mailto:angelo.poletti@unimi.it) (A. Poletti), [rita.galbiati@unimi.it](mailto:rita.galbiati@unimi.it) (M. Galbiati).

<sup>1</sup> These authors equally contributed to this work.

Point mutations in human Cu/Zn superoxide dismutase 1 (*SOD1*) gene have been found in about 20% of fALS cases, while alterations of wild-type (wt) *SOD1* properties have been reported in some sALS patients (Bendotti and Carri, 2004; Pasinelli and Brown, 2006). sALS and fALS are clinically indistinguishable, and thus, animal and cellular models expressing the mutated form of *SOD1* with glycine 93 substitution with alanine (G93A) are widely used to study disease mechanisms (Pasinelli and Brown, 2006). The general incidence of ALS ranges from 2 to 5 per 100,000 person-years, with a prevalence of 7–9 per 100,000 persons. Interestingly, men have a higher risk of developing ALS than women. The male/female ratio of ALS incidence is 2.5 in younger groups (when androgen levels are high in males), it declines to 1.4 in older groups (Manjaly et al., 2010), and it becomes 1:1 at ages above 60 years (when androgen levels decrease in males) (Groeneveld et al., 2004; Haverkamp et al., 1995; Logroscino et al., 2010). Moreover, women with ALS display an older average age of

onset (Rudnicki, 1999). Notably, gender differences have been detected also in transgenic mice expressing G93A-SOD1. In these mice, disease progression is significantly more aggressive in males than females (Heiman-Patterson et al., 2005; Veldink et al., 2003). Male hormonal steroids might have a role in this gender-related difference in ALS. Indeed, anabolic androgenic steroid abuse has been suggested to be responsible for the increased ALS prevalence in Italian soccer and American football players (Abel, 2007; Beghi et al., 2010; Belli and Vanacore, 2005; Chio et al., 2005; Piazza et al., 2004). In addition, reduced serum levels of androgens protected G93A-SOD1 mice from the toxicity of the mutant protein, whereas excessive androgen stimulation resulted in deterioration of motor function and reduced life span (Aggarwal et al., 2014).

A large body of evidence supports the idea that ALS is not purely a motoneuron disease. Inflammation of nervous tissue and muscle degeneration contribute to motoneuron death in a non-cell-autonomous fashion (Boillee et al., 2006). Toxicity to motoneurons might also derive from their target muscular cells. Indeed, although in G93A-SOD1 mice the reduction of the mutant protein in skeletal muscles has no effect on disease progression (Miller et al., 2006), selective expression of G93A-SOD1 in the skeletal muscle results in progressive muscle atrophy (Corti et al., 2009; Dobrowolny et al., 2008; Levine et al., 2013). Furthermore, muscle dysfunction and neuromuscular junction degeneration occur long before disease onset and motoneuron death (Fischer et al., 2004; Frey et al., 2000; Kennel et al., 1996). Several disease-associated alterations of the regenerative potential of skeletal muscles occur in the muscle of G93A-SOD1 mice; in particular, we and other authors previously reported modifications in the expression of TGF $\beta$ 1 (Galbiati et al., 2012, 2014; Si et al., 2015). It is a pleiotropic growth factor with detrimental roles on muscular functions and regeneration (Kollias and McDermott, 2008; McLennan and Koishi, 2002). Nonetheless, TGF $\beta$ 1 enhances survival, development, and maintenance of neurons (Bottner et al., 2000). TGF $\beta$ 1 functions are mediated by type 1 and type 2 transmembrane receptors (TGFBR) forming a serine/threonine kinase complex. TGF $\beta$ 1 binds to a type 2 homodimer receptor that recruits and phosphorylates type 1 receptor to phosphorylate small mother against decapentaplegic 2 (SMAD2) and SMAD3. Phosphorylated SMAD2 and SMAD3 bind SMAD4, translocate to the nucleus, and act as transcription factors (reviewed by Shi and Massague, 2003).

In ALS patients, TGF $\beta$ 1 levels are increased in both the serum and cerebrospinal fluid, and they positively correlate with disease duration (Houi et al., 2002; Ilzecka et al., 2002; Peters et al., 2017). Notably, a reduced activity of the transcription factor ZNF (Zinc Finger Protein) 512B, which is a regulator of TGF $\beta$ 1 signaling pathway, has been linked to an increased susceptibility to ALS (Iida et al., 2011). In lumbar ventral horn motoneurons of G93A-SOD1 mice, TGFBR2 levels are increased (Phatnani et al., 2013). Moreover, an aberrant nucleocytoplasmic transport with an accumulation of cytoplasmic pSMAD2/3 immunoreactivity has been reported in ALS (Nakamura et al., 2008; Zhang et al., 2006). However, few data are available on TGF $\beta$ 1 signaling in the ALS muscle (Si et al., 2015).

In this study, we analyzed the activation of TGF $\beta$ 1 signaling in both the spinal cord and muscle of SOD1-G93A mice. We performed the analyses at presymptomatic (PS) and symptomatic (S) stage, taking into account gender-related effects. We also evaluated the gene expression of TGF $\beta$ 1 and its signaling pathway in the muscle of a cohort of ALS patients. The results demonstrate that in the spinal cord, Tgf $\beta$ 1 expression is reduced at PS stage without gender differences, indicating a possible lack of its neuroprotective effect on motoneurons. In the skeletal muscle at PS stage, Tgf $\beta$ 1 expression is induced selectively in males, whereas at the S stage, it is increased in both ALS mouse- and human-derived specimens. TGF $\beta$ 1 signaling pathway is dysregulated mainly at the muscular level and this can negatively reflect on muscle functionality.

## 2. Materials and methods

### 2.1. Animals

Mice were maintained according to the institutional guidelines that are in compliance with national (D.L. 26/2014) and European laws and policies (2010/63/UE). All the experimental procedures were approved by the Italian Ministry of Health. All the animals were kept under controlled temperature and humidity conditions, with dark/light cycles of 12 hours. Food and water were supplied *ad libitum*.

#### 2.1.1. ALS model

BL6JL-Tg (SOD1)2Gur/J (stock number 002297, The Jackson Laboratory) male mice or BL6JL-Tg (SOD1-G93A)2Gur/J (stock number 002726, The Jackson Laboratory) male mice were crossed with wt female mice purchased (stock number 100012, Charles River) or obtained in house by crossing C57Bl/6J female and SJL male mice. All the experiments were performed in mice coming from the F1 generation of the cross described previously. Non-transgenic (NTg) littermates were used as controls. The genotyping of the litters was conducted by PCR on tail biopsy DNA as previously described (Crippa et al., 2013; Galbiati et al., 2012). To evaluate disease stages, starting from the 8th week of age and twice a week, mice were tested for the deficits by rotarod, and hanging wire by the same operator as previously described (Aggarwal et al., 2014). Body weight loss was also monitored. Disease onset was set as the time at which the mouse permanently starts to lose body weight. Four mice per gender per genotype were anesthetized with isoflurane and sacrificed at 8 or 16 weeks of age, corresponding to PS or S stage of disease. Spinal cord and quadriceps muscles were rapidly collected after the sacrifice, snap-frozen on dry ice, and conserved at  $-80^{\circ}\text{C}$  until extraction.

#### 2.1.2. Spinal bulbar muscular atrophy model

Generation and genotyping of mice containing the exon 1 of the human androgen receptor gene with 113 CAG repeats (AR113Q mice) has been previously described (Rusmini et al., 2015; Yu et al., 2006a,b). Mice genetic background was C57Bl/6J. Females carrying 1 copy of AR113Q in the X chromosome were crossed with C57Bl/6J mice to maintain the colony. Genotypes were verified by PCR on tail DNA. Symptomatic mice of 24 weeks of age were anesthetized with isoflurane and sacrificed; quadriceps muscles were collected, snap-frozen, and maintained at  $-80^{\circ}\text{C}$ .

#### 2.1.3. Denervation model

Three-months-old NTg male mice were anesthetized with ketamine and xylazine. An incision was made through the skin and the upper region of the left gluteal muscle to expose the sciatic nerve, which was then cut 1–2 mm distal to the sciatic notch. The proximal portion of the nerve was sutured to prevent errant reinnervation of the gastrocnemius muscle. Right sciatic nerve was exposed and utilized as sham internal control in each animal. Mice were sacrificed 7 days later, and gastrocnemius muscles were collected, snap-frozen, and conserved at  $-80^{\circ}\text{C}$ .

### 2.2. Human samples

All evaluations involving anonymized controls and patients and experiments involving muscle tissue samples were performed in accordance with relevant guidelines and regulations and were approved by the University of Padova Ethics Committee for Clinical Experimentation. Written informed consent to study procedures was obtained from each patient, or his legal guardians. Confidentiality was guaranteed by assigning a study code to each patient.

Biopsies were conserved in a genetic biobank supported by Telethon, Italy, fully complying with highest quality standards, according to rigorous ethical principles complying with Italian laws and International Recommendations. All patients were clinically affected with the definite ALS diagnosis, according to the revised El Escorial criteria (Brooks et al., 2000), and were followed at Neuro-muscular Clinic of the University of Padova. [Supplementary Table 1](#) reports demographic and clinical data of 23 ALS patients enrolled (10 females and 13 males). Control biopsies were obtained from healthy age-matched subjects (9 females and 5 males), who had undergone hip arthroprosthesis. Muscle biopsies were obtained using an open biopsy procedure and 100–200 mg of muscle tissue collected. All biopsies were immediately frozen in liquid nitrogen for histopathology and biochemical analyses and stored at  $-80^{\circ}\text{C}$  until analyzed (Borgia et al., 2017). Total RNA was isolated from frozen muscle biopsies using TRI Reagent (Sigma-Aldrich), according to the manufacturer's instructions.

### 2.3. Cell cultures

The myoblast C2C12 cell line was originally obtained from the American Type Culture Collection (Rockville, MD). The cell line was routinely maintained in high glucose (4500 mg/L) Dulbecco's modified Eagle's medium (Biochrom KG, Berlin, Germany) supplemented with 4 mM glutamine, 1 mM sodium pyruvate, 100 U/mL penicillin, 100  $\mu\text{g}/\text{mL}$  streptomycin, and 10% fetal bovine serum (Thermo Fisher Scientific, Monza, Italy) at  $37^{\circ}\text{C}$  with 5%  $\text{CO}_2$ . The plasmids pcDNA3-wt-SOD1 and pcDNA3-G93ASOD1 (Galbiati et al., 2012) were transiently transfected into C2C12 using Lipofectamine 2000 (Thermo Fisher Scientific) following manufacturer's instructions. Briefly, 60,000 cells were plated in 12-well and transfected with 1.6  $\mu\text{g}$  of DNA, and 4  $\mu\text{L}$  of Lipofectamine/well. Controls were mock-transfected. Cells were harvested for RNA isolation at 48 hours after transfection.

### 2.4. Western blotting assay

To obtain total proteins from the spinal cord or muscle, samples were homogenized in lysis buffer (phosphate-buffered saline, pH 7.4, supplemented with 1% Nonidet P-40, protease inhibitor cocktail [Roche Diagnostic Spa, Monza, Italy], phosphatase inhibitors [sodium vanadate 100 mM and sodium fluoride 100 mM], and EDTA 1  $\mu\text{M}$ ), with TissueLyser II and stainless steel glass beads (Qiagen, Milano, Italy). Crude extracts were centrifuged for 10 minutes at 5000 rpm at  $4^{\circ}\text{C}$  to remove particulate matter. Supernatant proteins concentration was determined by the bicinchoninic acid method (BCA assay, EuroClone, Pero, Italy). Western immunoblot analysis was performed on 12% sodium dodecyl sulfate polyacrylamide gel electrophoresis loading 15  $\mu\text{g}$  of total proteins. Samples were then electrotransferred to nitrocellulose membranes 0.45  $\mu\text{m}$  (Bio-Rad Laboratories, Hercules, CA) using a semidry transfer apparatus (Trans-Blot Turbo Transfer System, Bio-Rad Laboratories). Nitrocellulose membranes were treated overnight with a blocking solution containing 5% nonfat dry milk in TBS-T (Tris-buffered saline with 0.1% Tween 20) and then incubated with the right primary antibodies overnight at  $4^{\circ}\text{C}$  (anti-TGFB1 R&D, dilution 1:1000; anti-Smad2/3 Merck Millipore 1:1000; anti-GAPDH Santa Cruz Biotechnology 1:1000).

Immunoreactivity was detected using the following secondary peroxidase-conjugated antibodies: goat anti-rabbit (Santa Cruz Biotechnology dilution 1:5000) was used to identify anti-Smad2/3, and anti-GAPDH; goat anti-mouse (Santa Cruz Biotechnology dilution 1:5000) was used to identify the anti-TGFB1 antibody.

The immunoreactive regions were then visualized using the enhanced chemiluminescence detection kit reagents (Clarity

Western ECL substrate; Bio-Rad Laboratories). A ChemiDoc XRS System (Bio-Rad Laboratories) was used for the image acquisition. Optical intensity of samples assayed was detected and analyzed using the Image Lab software (Bio-Rad Laboratories).

### 2.5. RNA extraction and RT-qPCR

Total RNA from frozen spinal cords, muscles, or C2C12 cells were extracted using the TRI Reagent in accordance to the manufacturer's protocol (Sigma-Aldrich). RNA was dissolved in RNase-free water and quantified. Total RNA (1  $\mu\text{g}$ ) was treated for 15 minutes at room temperature with 1U of DNaseI (Sigma Aldrich). Samples were reverse-transcribed using the HighCapacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific) according to the manufacturer's instructions.

Real-time PCR was performed using the CFX 96 Real-Time System (Bio-Rad Laboratories) in a 10  $\mu\text{L}$  total volume, using the iTaq SYBR Green Supermix (Bio-Rad Laboratories), and with 500 nm primers. PCR cycling conditions were as follows:  $94^{\circ}\text{C}$  for 10 minutes, 40 cycles at  $94^{\circ}\text{C}$  for 15 seconds, and  $60^{\circ}\text{C}$  for 1 minute. Primers for selected genes were designed using the program Primer 3 and purchased from Eurofins Genomics (Ebersberg, Germany). Primer sequences are reported in [Supplementary Table 2](#). Melting curve analysis was performed at the end of each PCR assay as a control for specificity. Data have been normalized to the amount of the housekeeping gene ribosomal protein lateral stalk subunit P0 (*Rplp0*) or *RPLP0*, whose expression, to our experience, is stable across samples of the spinal cord and muscle. Sample  $C_t$  values were used for target relative quantification through the  $\Delta\Delta C_t$  calculation. All the data have been referred to the female 8-week-old NTg mouse group, since, from preliminary experiments in muscle, it was the group with the lowest expression of *Tgfb1* mRNA. The  $N$ -fold changes in gene expression were obtained transforming data by the equation  $2^{-\Delta\Delta C_t}$ .

### 2.6. Statistical analysis

Statistical analysis was performed through two-tailed Student  $t$ -test for comparisons between 2 groups (control vs. axotomized, NTg vs. spinal bulbar muscular atrophy [SBMA]), one-way analysis of variance followed by Tukey post hoc test for group comparison (pcDNA3 vs. wt-SOD1 and G93A-SOD1), and two-way analysis of variance for group comparisons followed by Bonferroni post hoc test to determine specific group pair(s) statistical difference, using the PRISM software (GraphPad, San Diego, CA). Details of statistical analyses have been reported in the [Supplementary Data](#).

## 3. Results

### 3.1. TGFB1 expression in ALS tissues

We have previously shown that in the skeletal muscle of PS male G93A-SOD1 mice, *Tgfb1* gene expression is upregulated compared to age-matched NTg male mice (Galbiati et al., 2012). In addition, we found that the androgenic/anabolic steroid nandrolone further enhances *Tgfb1* expression in these mice (Galbiati et al., 2012). Here we evaluated whether gender affects *Tgfb1* expression in the same ALS mouse model. The study has been performed on 8 (PS)- and 16 (S)-week-old G93A-SOD1 mice. As control, we used age-matched NTg mice and Tg mice expressing human wt-SOD1 (wt-SOD1). We analyzed *Tgfb1* mRNA transcript levels in the spinal cords and quadriceps muscles of both PS and S, male and female mice; at each time point, 4 mice per gender per genotype were used. In samples derived from the spinal cord at the PS stage, *Tgfb1* mRNA levels were reduced in both female and male G93A-SOD1 mice compared to age-


matched NTg and wt-SOD1 mice (Fig. 1A; \* $p < 0.05$ , \*\* $p < 0.01$ ). The decreased *Tgfb1* mRNA expression was reverted at the S stage; in fact, *Tgfb1* mRNA levels increased in females and males when compared to the levels detected at PS stage of G93A-SOD1 mice (Fig. 1A; \*\* $p < 0.01$ , \*\*\* $p < 0.001$ ). *Tgfb1* gene expression in NTg and in wt-SOD1 mice remained unchanged at all the examined conditions.

In the quadriceps muscles at the S stage, *Tgfb1* mRNA levels were found to be greatly increased in female and male G93A-SOD1 mice compared to G93A-SOD1 mice at PS stage and to age-matched NTg and wt-SOD1 mice (Fig. 1B; \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ ). At the PS stage, *Tgfb1* mRNA levels were significantly upregulated only in male G93A-SOD1 animals (\* $p < 0.05$  vs. age-matched NTg male mice) (Fig. 1B). Combined with our previous data, this observation corroborates the notion that at the muscular level, male androgens might exert a detrimental role in ALS because they exacerbate some of the alterations induced by G93A-SOD1 (Aggarwal et al., 2014; Galbiati et al., 2012).

Because data from wt-SOD1 mice did not differ from those obtained from NTg animals, we decided to use the latter model as a control for subsequent analyses.

Next, we analyzed TGFB1 protein expression (Fig. 1C–D). Western blot analysis of spinal cord lysates showed that at S stage, TGFB1 levels were increased when compared to PS stage both in male and female mice, even if this difference was not statistically significant (Fig. 1C). In the muscle at PS stage, TGFB1 levels were increased specifically in male G93A-SOD1 mice as compared to NTg mice (Fig. 1D; \* $p < 0.05$ ). At the S stage, TGFB1 levels were increased in female and male G93A-SOD1 mice, as compared to NTg mice (Fig. 1D; \* $p < 0.05$ ; \*\*\* $p < 0.001$ ). Obtained data have also been presented in Table 1 (changes during the disease course in female and male G93A-SOD1 mice) and Table 2 (changes of mRNA and protein levels in female and male G93A-SOD1 mice vs. NTg mice).

We next asked whether alteration in the gene expression of TGFB1 also occurs in the muscle of female and male ALS patients.



**Fig. 1.** TGFB1 levels in ALS tissues. (A and B) RT-qPCR analyses of *Tgfb1* mRNA performed on total RNA extracted from the spinal cord (A) or quadriceps muscles (B) of female and male mice [NTg (nontransgenic), Tg expressing either the wild-type human SOD1 transgene (wt-SOD1) or the G93A mutant form of human SOD1 (G93A-SOD1)], at 8 and 16 weeks of age. Data have been normalized to *Rplp0* mRNA, referred to the levels determined in female NTg mice at 8 weeks of age (internal reference), and expressed as fold changes. Each bar represents the mean  $\pm$  s.e.m. of 4 independent replicates. \* $p < 0.05$ ; \*\* $p < 0.01$ ; \*\*\* $p < 0.001$ . (C and D) Representative immunoblot and densitometric analysis of TGFB1 and GAPDH proteins extracted from spinal cords (C) or quadriceps muscles (D) of female and male NTg, and G93A-SOD1 mice, at 8 or 16 weeks of age. GAPDH was used to normalize protein loading. Each bar represents the mean  $\pm$  s.e.m. of independent replicates (3 for the spinal cord and 4 for quadriceps). \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ . (E) RT-qPCR analyses of TGFB1 mRNA levels from muscle biopsies of male and female human controls and ALS patients. Data have been normalized to RPLP0 mRNA, referred to the levels determined in female controls, and expressed as fold changes. Disease effect  $p = 0.0003$ ; gender effect  $p = 0.0196$ ; \* $p < 0.05$ ; \*\* $p < 0.01$ . Statistical analysis has been performed through two-way ANOVA for group comparisons followed by Bonferroni post hoc test. Abbreviation: ALS, amyotrophic lateral sclerosis.

Demographic and clinical data of controls and ALS patients have been reported in [Supplementary Table 1](#). As reported in [Fig. 1E](#), the expression of *TGFB1* mRNA was increased in female and male sALS patients (disease effect  $p = 0.0003$ ). Notably, a statistically significant gender effect ( $p = 0.0196$ ) was observed related to *TGFB1* mRNA levels. These observations indicate that gene expression of *TGFB1* is upregulated in the skeletal muscle of ALS mice at late stage of disease as in sALS patients.

### 3.2. Altered *TGFB1* signaling in the ALS spinal cord and muscle

Not only *TGFB1* but also its signaling pathway is dysregulated in different neurodegenerative diseases ([Phatnani et al., 2013](#)). Thus, we evaluated possible variations of the mRNA levels of *Tgfb2*, both in the spinal cord and quadriceps muscle of PS and S G93A-SOD1 mice. In the spinal cord, *Tgfb2* expression was not altered at PS stage, whereas it was increased in female and male G93A-SOD1 mice at S stage ([Fig. 2A](#); \* $p < 0.05$ ; \*\* $p < 0.01$ ). In quadriceps muscles, *Tgfb2* expression was unchanged at both PS and S stages ([Fig. 2B](#)).

Then, we evaluated the expression of the canonical intracellular mediators of *TGFB1* signaling pathway, that are SMAD proteins. In spinal cord samples, *Smad2* expression did not change at PS stage, whereas it decreased in female and male mice during disease progression ([Fig. 3A](#); \* $p < 0.05$ , \*\* $p < 0.01$ ), while *Smad3* expression in G93A-SOD1 mice at S stage showed gender differences ([Fig. 3B](#); \* $p < 0.05$ ). In quadriceps muscles, *Smad2* mRNA levels were decreased in S stage female and male mice compared to those in PS stage ([Fig. 3C](#); \* $p < 0.05$ ; \*\* $p < 0.01$ ). *Smad3* mRNA levels were upregulated in the muscle of S stage female and male mice, compared to those in PS stage ([Fig. 3D](#); \* $p < 0.05$ , \*\* $p < 0.01$ ). By Western blot analysis of spinal cord lysates, we did not find any significant changes in the levels of SMAD2 and SMAD3 except for an increase in the SMAD3 levels in female G93A-SOD1 mice during the disease course ([Fig. 3E–G](#); \* $p < 0.05$ ). In quadriceps muscles, we found that SMAD2 levels are upregulated selectively in males at PS and S stage ([Fig. 3H and J](#); \* $p < 0.05$ ; \*\* $p < 0.01$ ). SMAD3 levels were increased at PS and S stage both in male and female mice ([Fig. 3H and K](#); \* $p < 0.05$ ). We also analyzed the expression of *Smad4*, and we found that in the spinal cord of G93A-SOD1 mice, *Smad4* mRNA levels are reduced during disease progression in female, but not in male mice ([Fig. 4A](#); \* $p < 0.05$ ). In quadriceps, *Smad4* mRNA levels were reduced at the S stage compared to PS stage in both male and female G93A-SOD1 mice ([Fig. 4B](#); \*\* $p < 0.01$ ; \*\*\* $p < 0.001$ ).

We then evaluated possible alteration in the *TGFB1* signaling pathway in the muscle of female and male ALS patients. As reported

**Table 1**  
S versus PS G93A-SOD1 mice

Gene/protein name	Spinal cord		Muscle	
	F	M	F	M
<i>Tgfb1</i>	↑	↑	↑↑	↑↑
TGFB1	–	–	–	–
<i>Tgfb2</i>	↑	↑	–	–
<i>Smad2</i>	↓	↓	↓	↓
SMAD2	–	–	–	↓
<i>Smad3</i>	–	–	↑	↑
SMAD3	↑	–	–	–
<i>Smad4</i>	↓	–	↓	↓
<i>Pax7</i>	–	–	↓	↓
<i>Col1a1</i>	–	–	↓	↓
<i>Fn</i>	–	–	↓	↓

Summary table showing changes of mRNA and protein levels during the disease course (from 8 to 16 wk of age) in the spinal cord or muscle of female (F) and male (M) G93A-SOD1-expressing mice.

Key: PS, presymptomatic (8 wk of age); S, symptomatic (16 wk of age); ↑, increased; ↓, decreased; –, unchanged.

**Table 2**  
G93A-SOD1 versus NTg mice

Age (wk)	Spinal cord				Muscle			
	F		M		F		M	
	8	16	8	16	8	16	8	16
<i>Tgfb1</i>	↓	↑	↓	–	–	↑↑	↑	↑↑
TGFB1	–	–	–	–	–	↑	↑	↑↑
<i>Tgfb2</i>	–	↑	–	↑	–	–	–	–
<i>Smad2</i>	–	–	–	–	–	–	–	–
SMAD2	–	–	–	–	–	–	↑	↑
<i>Smad3</i>	–	–	–	–	–	–	–	–
SMAD3	–	–	–	–	↑	↑	↑↑	↑↑
<i>Smad4</i>	–	–	–	–	–	↓	–	↓
<i>Pax7</i>	–	–	–	–	–	↓	–	–
<i>Col1a1</i>	–	–	–	–	–	↓	–	↓
<i>Fn</i>	–	–	–	–	–	↓	–	↓

Summary table showing changes of mRNA and protein levels between female (F) and male (M) G93A-SOD1 versus NTg mice in the spinal cord and muscle at different time points of the disease course [8 (presymptomatic) and 16 (symptomatic) weeks of age].

Key: ↑, increased; ↓, decreased; –, unchanged.


in [Fig. 5](#), the levels of SMAD3 mRNA were diminished in female patients, while *TGFB2*, *SMAD2*, and *SMAD4* did not change in ALS patients versus controls (\*\* $p < 0.01$ ). A statistically significant gender effect was observed in controls for *SMAD2* and *SMAD3* mRNA (\*\* $p < 0.01$ ; \*\*\* $p < 0.001$ ).

These results indicate that the expression of *TGFB1* effectors, *TGFB2*, *SMAD2*, *SMAD3*, and *SMAD4*, is altered in the spinal cord, and specially in the muscle of ALS mice, and some of these alterations are recapitulated in ALS patients. In [Tables 1 and 2](#), we have summarized results grouped for changes during the disease course or between male and female in ALS animals versus NTg mice.

### 3.3. *TGFB1*-related functions in the ALS muscle

*TGFB1* suppresses muscle differentiation by inhibiting the expression of muscle-specific genes ([Galbiati et al., 2012](#); [Massague et al., 1986](#); [Olson et al., 1986](#)). Moreover, *TGFB1* hampers muscle regeneration in muscular diseases by inhibiting satellite cell proliferation and myofiber fusion ([Burks et al., 2011](#); [Cohn et al., 2007](#)). During myogenesis, satellite cells are mainly regulated by the transcription factor paired box protein 7 (PAX7), which in turn is known to be negatively modulated by *TGFB1* ([Braga et al., 2012](#)). Thus, we analyzed whether *Pax7* expression is altered in the muscle of G93A-SOD1 mice. The results reported in [Fig. 6A](#) show that *Pax7* mRNA levels are reduced in female and male G93A-SOD1 mice, at S stage compared to PS stage (\*\* $p < 0.001$ ). To evaluate whether this effect could be generally ascribed to myofiber denervation, we measured *Pax7* expression in 2 other conditions characterized by motoneuron loss: (1) muscles derived from acutely axotomized NTg mice; (2) muscles derived from a mouse model of SBMA or Kennedy's disease, which represents another type of motoneuron disease sharing progressive denervation with ALS ([La Spada et al., 1991](#); [Lieberman et al., 2014](#)). [Fig. 6B](#) indicates that denervation due to axotomy (7 days) leads to a decrease of *Pax7* expression (\*\* $p < 0.01$ ). *Pax7* expression was increased in the muscle of SBMA mouse model at S stage (24 weeks) compared to age-matched NTg mice ([Fig. 6C](#); \*\*\* $p < 0.001$ ).

Because in different muscle disorders, *TGFB1* promotes an aberrant differentiation of myogenic cells to myofibroblasts inducing fibrosis ([Burks and Cohn, 2011](#); [Li et al., 2004](#)), and muscular fibrosis is a pathological feature of ALS ([Qi et al., 2015](#)), we analyzed in G93A-SOD1 mice the mRNA expression of 2 extracellular matrix proteins, whose increase in expression represents a hallmark of fibrosis: collagen 1 alpha 1 (*Col1a1*) and fibronectin (*Fn*). We found that in the muscle of NTg mice, the expression of



**Fig. 2.** *Tgfb2* mRNA is upregulated in the spinal cord of ALS mice. RT-qPCR analyses of *Tgfb2* mRNA performed on total RNA extracted from the spinal cord (A) and quadriceps muscle (B) of female and male mice [NTg (nontransgenic), and Tg mice expressing the G93A mutant form of human SOD1 (G93A-SOD1)], at 8 (presymptomatic stage) and 16 (symptomatic stage) weeks of age. Data have been normalized to *Rplp0* mRNA, referred to the levels determined in female NTg mice at 8 weeks of age (internal reference), and expressed as fold changes. Each bar represents the mean  $\pm$  s.e.m. of 4 independent replicates. \* $p < 0.05$ , \*\* $p < 0.01$ . Statistical analysis has been performed through two-way ANOVA for group comparisons followed by Bonferroni post hoc test. Abbreviation: ALS, amyotrophic lateral sclerosis.

*Col1a1* decreases with age. In G93A-SOD1 mice, *Col1a1* expression was further diminished at S stage as compared to PS stage and to age-matched NTg mice (Fig. 7A; \* $p < 0.05$ ; \*\* $p < 0.01$ ; \*\*\* $p < 0.001$ ). The expression of *Fn* was reduced in the muscle of both female and male G93A-SOD1 mice at S stage compared to PS stage and to age-matched NTg mice (Fig. 7B; \*\* $p < 0.01$ , \*\*\* $p < 0.001$ ). To determine whether the effect on *Col1a1* and *Fn* gene expression in G93A-SOD1 is due to the presence of the mutated form of SOD1 or to denervation, we measured their expression in the axotomized mouse muscle. Fig. 7C and D shows that denervation due to acute axotomy cause a dramatic increase in *Col1a1* and *Fn* expression (\* $p < 0.05$ ; \*\* $p < 0.01$ ), suggesting that the reduction in the expression of these 2 genes in the muscle of G93A-SOD1 is not due to muscle denervation but probably to the presence of the G93A-SOD1. To validate this hypothesis, we analyzed the expression of *Col1a1* and *Fn* in C2C12 myoblasts transiently transfected with G93A-SOD1 (Galbiati et al., 2012; Onesto et al., 2011). *Tgfb1* mRNA levels were increased in C2C12 expressing G93A-SOD1 as compared to control myoblasts (pcDNA3) (Fig. 7E; \* $p < 0.05$ ), and *Col1a1* and *Fn* mRNA levels were decreased (Fig. 7F and G; \* $p < 0.05$ ). No effect was detected in cells transfected with the wt-SOD1.

#### 4. Discussion


In the last few years, it has become clear that ALS is a non-cell-autonomous disease of motoneurons and that other cell types are involved and modulate ALS onset and progression. An emerging body of evidence supports the idea that muscle cells could primarily contribute to G93A-SOD1-mediated toxicity (Crippa et al., 2013; Dobrowolny et al., 2008; Galbiati et al., 2012; Onesto et al., 2011; Wong and Martin, 2010). Gender is a risk factor for developing ALS (Manjaly et al., 2010). Consistent with this idea, our results show that, although TGFB1 is highly expressed in the muscle at the S stage both in female and male mice, the increase of TGFB1 takes place earlier in male than in female (at the PS stage) mice. Because *Tgfb1* is an androgen-responsive gene (Singh et al., 2009), it is possible that the increased risk of ALS in males is linked to the higher serum levels of male sex steroids. The hypothesis of TGFB1 involvement in ALS is corroborated by the fact that its gene expression is also increased in the muscle of ALS patients. This result is in agreement with the increase of TGFB3 in the ALS patient muscle reported by other authors (Pradat et al., 2012). An inconsistency appears to be present between humans and mice at the S stage. This may merely reflect the fact that G93A-SOD1 mice have an identical genetic background and a severe and constant disease progression, while sALS patients are characterized by highly

variable genetic background and their disease progression may be more directly affected by gender differences because sex hormone levels greatly change throughout life. High TGFB1 plasma levels have been detected in ALS patients, with a significant positive correlation with disease duration (Houli et al., 2002; Ilzecka et al., 2002; Peters et al., 2017). On the contrary, the expression levels of endogenous *Tgfb1* mRNA at the end stage negatively correlated with the survival of G93A-SOD1 mice (Endo et al., 2015). All these evidences indicate that a prolonged increase of TGFB1 levels might promote a more rapid disease progression, and that TGFB1 could be a potential biomarker of ALS progression in males and females (Peters et al., 2017).

TGFB1 has a protective role in neurons (Kriegelstein et al., 2002), and reduced neuronal TGFB signaling is implicated in age-dependent neurodegeneration (Tesseur et al., 2006). Gene expression analysis in the spinal cord of G93A-SOD1 mice showed decreased *Tgfb1* mRNA levels at the PS stage, possibly indicating a lack of neuroprotective effects in the early stages of disease, which may in turn contribute to the death of motoneurons at later stages. In the ALS mouse spinal cord, *Tgfb1* mRNA increases with disease progression, a phenomenon that can be explained by the development of reactive astrogliosis (Phatnani et al., 2013). Indeed, astrocyte-derived TGFB1 accelerates ALS progression, while the same parameter is counteracted by the administration of a TGFB inhibitor (Endo et al., 2015). Furthermore, the effects of TGFB1 are also mediated by the inhibition of microglial activation with the consequent reduction of neuroprotective properties of microglial cells (Endo et al., 2015).

We found that *Tgfb2* mRNA levels are increased in the spinal cord, but not in the muscle, of G93A-SOD1 mice at S stage. These results are in agreement with previous studies showing a high TGFB2 immunoreactivity in spinal cord motoneurons of mice expressing G93A-SOD1, which correlates with reactive astrogliosis and disease progression (Phatnani et al., 2013). Furthermore, the tissue-specific modulation of the *Tgfb2* expression could also mediate different roles of TGFB1 in the muscle and spinal cord. Increased levels of *Tgfb2* in the spinal cord have been reported also by other authors both in human and mouse spinal cord samples (D'Arrigo et al., 2010; Kirby et al., 2011).


Different *Tgfb2* expression levels might also correlate with dysregulation(s) of the intracellular pathway mediating TGFB effects. We found that *Smad2* expression in the spinal cord of ALS mice decreases along disease course, yet protein levels were unchanged. It is unclear which factors differentially regulated RNA (transcription, stability) and protein (translation, posttranslational modification, clearance) levels. In the muscle, *Smad2* mRNA was reduced and



**Fig. 3.** SMAD levels in ALS tissues are dysregulated. RT-qPCR analyses of the mRNA levels of *Smads2* and 3 performed on total RNA extracted from the spinal cord (A and B) or quadriceps muscles (C and D) of female and male mice [NTg (nontransgenic), Tg expressing the G93A mutant form of human SOD1 (G93A-SOD1)], at 8 (presymptomatic stage) or 16 (symptomatic stage) weeks of age. Data have been normalized to *Rplp0* mRNA, referred to the levels determined in female NTg mice at 8 weeks of age (internal reference), and expressed as fold changes. Each bar represents the mean  $\pm$  s.e.m. of 4 independent replicates (\* $p < 0.05$ , \*\* $p < 0.01$ ). (E–K) Representative immunoblot and densitometric analyses of SMAD2 and 3. Proteins were extracted from spinal cords or quadriceps muscles of female and male NTg, and G93A-SOD1 mice, at 8 or 16 weeks of age. GAPDH was used to normalize protein loading. Each bar represents the mean  $\pm$  s.e.m. of independent replicates (3 for the spinal cord and 4 for the quadriceps muscle). Images have been cropped from different parts of the same gel, and full-length blots are included in [Supplementary Fig. 1](#). \* $p < 0.05$ ; \*\* $p < 0.01$ . Statistical analysis has been performed through two-way ANOVA for group comparisons followed by Bonferroni post hoc test. Abbreviation: ALS, amyotrophic lateral sclerosis.

*Smad3* mRNA was increased with disease progression. Nonetheless, SMAD2 and SMAD3 were increased at S stage. An increased SMAD3 expression in the patient muscle was reported also by [Pradat et al., 2012](#). Although SMAD2 and SMAD3 are both receptor-activated SMADs, SMAD2 is unable to bind DNA directly, whereas SMAD3 binds DNA. Furthermore, in some systems, SMAD2 and SMAD3 are antagonists, suggesting that they trigger different biological

response ([Labbe et al., 1998](#)). In addition, cultured hepatic cells turning to fibrogenic lineage show decreased SMAD2 expression accompanied by activation of SMAD3 ([Dooley et al., 2000](#)). Thus, SMAD2 and SMAD3 mediate different cellular responses, and this is also supported by data showing that *Smad2* knockout is lethal at the embryonic stage, whereas *Smad3* knockout mice survive to adulthood. Furthermore, to be imported into the nucleus, phosphorylated




**Fig. 4.** *Smad4* mRNA levels are decreased in the ALS muscle. RT-qPCR analyses of *Smad4* mRNA performed on total RNA extracted from the spinal cord (A) or quadriceps muscles (B) of female and male mice [NTg (nontransgenic), and Tg expressing the G93A mutant form of human SOD1 (G93A-SOD1)], at 8 (presymptomatic stage) or 16 (symptomatic stage) weeks of age. Data have been normalized to *Rplp0* mRNA, referred to the levels determined in female NTg mice at 8 weeks of age (internal reference), and expressed as fold changes. Each bar represents the mean  $\pm$  s.e.m. of 4 independent replicates. \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ . Statistical analysis has been performed through two-way ANOVA for group comparisons followed by Bonferroni post hoc test. Abbreviation: ALS, amyotrophic lateral sclerosis.


SMAD3 associates with importin-beta in the cytoplasm, whereas phosphorylated SMAD2 is autonomously imported into the nucleus (Kurisaki et al., 2001). Nakamura et al. proposed that alteration of SMAD nuclear translocation may impair the neuroprotective TGF $\beta$  signaling, leading to neurodegeneration (Nakamura et al., 2008). SMAD4 is the protein that shuttles receptor-regulated SMADs into the nucleus, even if SMAD4-independent effects of TGF $\beta$  have been described (Hocevar et al., 1999). In line with the work of Saris et al., we found decreased *Smad4* expression in both the spinal cord and muscle, suggesting a further site of dysregulation of TGF $\beta$  intracellular signaling (Saris et al., 2013).

An excessive TGF $\beta$ 1 has been proposed to be a harmful factor in muscle (Burks and Cohn, 2011). TGF $\beta$ 1 profoundly influences the differentiation of myoblasts by inhibiting the induction of muscle-specific gene expression and myotube formation (Liu et al., 2001). TGF $\beta$ 1 targets one or more master regulators of myogenesis, such as PAX7. Indeed, impaired regenerative capacity concomitant with a progressive loss of satellite cells has been reported in *Pax7*-null

mice (von Maltzahn et al., 2013). Notably, we found that *Pax7* expression is decreased in the muscle of ALS mice at S stage, suggesting that the myogenic potential and the ability for tissue repair of ALS muscle is impaired. This result is in agreement with a previous work on G93A-SOD1 mice (Calvo et al., 2012) and has been confirmed in patient biopsies showing a reduction in mRNA levels of markers of satellite cells and early myogenesis (Jensen et al., 2016). In agreement, denervation induced by axotomy diminished *Pax7* mRNA levels. On the contrary, *Pax7* gene expression was increased in the muscle of SBMA mouse model. SBMA is another type of motoneuron pathology sharing some features with ALS (La Spada et al., 1991; Lieberman et al., 2014), and it is characterized by progressive death of motoneuron and denervation. This result indicates that the reduction of *Pax7* mRNA in the ALS muscle may be due to a specific action of G93A-SOD1 rather than to denervation alone and could lead to an impairment of muscle regeneration. TGF $\beta$ 1 promotes an aberrant differentiation of myogenic cells to myofibroblasts and induces fibrosis (Burks and Cohn, 2011; Li et al.,




**Fig. 5.** TGF $\beta$ 1 signaling in the muscle of ALS patients. RT-qPCR analyses of the mRNA levels for *TGFBR2* (A); *SMAD2* (B); *SMAD3* (C); *SMAD4* (D) in muscle biopsies of male and female human controls and ALS patients. Data have been normalized to *RPLP0* mRNA, referred to the levels determined in female controls (internal reference), and expressed as fold changes. Statistical analysis has been performed through two-way ANOVA for group comparisons followed by Bonferroni post hoc test. Gender effect for *Smad3*: \*\* $p < 0.01$ . Disease effect in female: \*\* $p < 0.01$ . Abbreviation: ALS, amyotrophic lateral sclerosis.



**Fig. 6.** *Pax7* mRNA expression in different models of denervated muscles. RT-qPCR analyses of the *Pax7* mRNA levels performed on total RNA extracted from (A) quadriceps muscles of female and male mice [NTg (non-transgenic), and transgenic expressing the G93A mutant form of human SOD1 (G93A-SOD1)], at 8 (presymptomatic stage) or 16 (symptomatic stage) weeks of age. Data have been normalized to *Rplp0* mRNA, referred to the levels determined in female NTg mice at 8 weeks of age (internal reference), and expressed as fold changes. Each bar represents the mean  $\pm$  s.e.m. of 4 independent replicates. \*\* $p < 0.01$ , \*\*\* $p < 0.001$ . (B) Gastrocnemius muscles of left axotomized nontransgenic mice (Axo). Right gastrocnemius muscles of the same animals were used as controls (Ctrl). Data have been normalized to the amount of *Rplp0* mRNA, referred to the levels determined in control muscles (internal reference), and expressed as fold changes. \*\* $p < 0.01$ . (C) Quadriceps muscles of male nontransgenic (WT) mice, and of knock-in AR113Q (SBMA) mice at 24 weeks of age (corresponding to symptomatic stage). Animals were age-matched. Data have been normalized to the levels determined in WT mice (internal reference), and expressed as fold changes. \*\*\* $p < 0.001$ . Statistical analysis has been performed through two-way ANOVA for group comparisons followed by Bonferroni post hoc test.

2004), which is a pathological feature of ALS (Qi et al., 2015). In fact, FN and COL1 protein levels were found to be greatly increased in the muscle of symptomatic ALS mice (Gonzalez et al., 2017). *Col1a1* gene expression was age dependent in NTg mice, in line with the normal age-related rearrangement of skeletal muscle fibers and of

the connective tissue network (Trappe, 2009). In contrast to increased protein levels, we found that *Col1a1* and *Fn* mRNA levels were much lower in symptomatic ALS mice. This effect was not due to denervation because the expression of these 2 extracellular matrix proteins is highly increased in the axotomized muscle. On



**Fig. 7.** Changes in *Col1a1* and *Fn* mRNA levels. (A and B) RT-qPCR analyses of *Col1a1* and *Fn* mRNA levels performed on total RNA extracted from quadriceps muscles of female and male mice [NTg (nontransgenic), and transgenic expressing the G93A mutant form of human SOD1 (G93A-SOD1)], at 8 (presymptomatic stage) or 16 (symptomatic stage) weeks of age. Data have been normalized to the amount of *Rplp0* mRNA, referred to the levels determined in female NTg mice at 8 weeks of age (internal reference), and expressed as fold changes. Each bar represents the mean  $\pm$  s.e.m. of 4 independent replicates. \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ . (C and D) RT-qPCR analyses of *Col1a1* and *Fn* mRNA levels performed on total RNA extracted from gastrocnemius muscles of left axotomized NTg mice (Axo). Right gastrocnemius muscles of the same animals were used as controls (Ctrl). Data have been normalized to the amount of *Rplp0* mRNA, referred to the levels determined in control muscles (internal reference), and expressed as fold changes. \* $p < 0.05$ , \*\* $p < 0.01$ . (E–G) RT-qPCR analyses of *Tgfb1*, *Col1a1*, and *Fn* mRNAs, performed on total RNA extracted from C2C12 cells transfected with wt human SOD1 (wt-SOD1) or G93A mutant form of human SOD1 (G93A-SOD1). Data have been normalized to the amount of *Rplp0* mRNA, referred to the levels determined in control cells (mock transfected, pcDNA3), which are taken as internal reference, and expressed as fold changes. Each bar represents the mean  $\pm$  s.e.m. of 4 independent replicates. \* $p < 0.05$ . Statistical analysis has been performed through two-way ANOVA for group comparisons followed by Bonferroni post hoc test.

the other hand, *Col1a1* and *Fn* mRNA reduction could be due to the decline in the ability to move mice during disease progression because poor mobility downregulates total muscular collagen synthesis (Ahtikoski et al., 2001). Furthermore, in C2C12 myoblasts, the expression of G93A-SOD1 led to decreased levels of *Col1a1* and *Fn* mRNA, indicating that mutant SOD1 could be directly responsible for modulation of *Col1a1* and *Fn* gene expression. It is possible that the decrease in collagen expression is an attempt to prevent collagen accumulation that leads to fibrosis; a similar mechanism has been proposed in hepatic cells (Cao et al., 2002). TGFB promotes *Col1a1* transcription through specific responsive sequences (Sato et al., 2004). Therefore, it remains to understand why the levels of *Col1a1* mRNA and *Fn* are reduced in the presence of high levels of TGFB1. A possible explanation comes from a work demonstrating that high doses of TGFB potentially suppress *Col1a1* transcription via the transcription factor CUX1 (Fragiadaki et al., 2011). However, also other authors reported decreased muscle *Col1a1* and *Fn* expression, respectively, in G86R-SOD1 mice or ALS patient (Gonzalez de Aguilar et al., 2008; Pradat et al., 2012).

## 5. Conclusions

The data here reported indicate that TGFB1 signaling pathway is altered in the ALS spinal cord and muscle. In the spinal cord, the PS reduction of *Tgfb1* expression could reflect a lack of its neuro-protective effect. In the muscle, the higher levels of TGFB1 could contribute to muscular atrophy because this correlates with an altered *Pax7* expression, and changes in extracellular matrix production. Androgen sensitivity of *Tgfb1* and its higher expression levels in males could also be a possible explanation of their higher risk of developing ALS. All together, these data increase the possibilities of new and complementary therapies to treat the disease or, at least, to delay muscle wasting.

## Disclosure

The authors have no actual or potential conflicts of interest.

## Acknowledgements

This work was supported by Fondazione Telethon, Italy (grant no. GGP14039 to AP, and TCP12013 to MP); Fondazione Cariplo, Italy (grant no. 2014-0686 to AP); Fondazione AriSLA, Italy (grant no. ALS\_HSPB8 to AP; ALS\_Granulopathy to AP); Association Française contre les Myopathies, France (AFM Telethon grant no. 16406 to AP and 18722 to MP); Università degli Studi di Milano e piano di sviluppo UNIMI—linea B (to PR, and to VC); Italian Ministry of Health (MinSal; grant no. GR-2011-02347198 to VC); Fondazione Regionale per la Ricerca Biomedica (FRRB; TRANS\_ALS, Rif. grant no. 2015-0023 to AP), Regione Lombardia, Italy (to AP); Italian Ministry of University and Research (MIUR), PRIN - Progetti di ricerca di interesse nazionale (grants no. 2015LFPNMN, and 2017F2A2C5 to AP). European Molecular Biology Organization (EMBO), short-term fellowship (grant no. 537-2015 to RC), and Muscular Dystrophy Association (479363 to MP). EU Joint Programme - Neurodegenerative Disease Research (JPND) project. The project is supported through the following funding organizations under the aegis of JPND [www.jpnd.eu](http://www.jpnd.eu). This project has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement no. 643417 (grant ID: 01ED1601 A, CureALS to AP), MIUR—Departmenti di Eccellenza, MIUR-FFABR to MG, MIUR-FFABR to PR, Kennedy's disease association (2018 grant to R.C.).

Authors' contributions: MG and AP designed and wrote the manuscript. MM performed the experiments; VC, RC, and PR

assisted in data analysis and interpretation; MEC, VF, GV, and BT helped in data collection. EM and MPi critically revised the manuscript and the figures. MPE provided ALS mice tissues and revised manuscript. GS provided RNA from patient muscle biopsies. All authors have provided final approval of the manuscript.

## Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.neurobiolaging.2019.07.001>.

## References

- Abel, E.L., 2007. Football increases the risk for Lou Gehrig's disease, amyotrophic lateral sclerosis. *Percept Mot. Skills* 104 (3 Pt 2), 1251–1254.
- Aggarwal, T., Polanco, M.J., Scaramuzzino, C., Rocchi, A., Milioto, C., Emionite, L., Ognio, E., Sambataro, F., Galbiati, M., Poletti, A., Pennuto, M., 2014. Androgens affect muscle, motor neuron, and survival in a mouse model of SOD1-related amyotrophic lateral sclerosis. *Neurobiol. Aging* 35, 1929–1938.
- Ahtikoski, A.M., Koskinen, S.O., Virtanen, P., Kovanen, V., Takala, T.E., 2001. Regulation of synthesis of fibrillar collagens in rat skeletal muscle during immobilization in shortened and lengthened positions. *Acta Physiol. Scand.* 172, 131–140.
- Beghi, E., Logroscino, G., Chio, A., Hardiman, O., Millul, A., Mitchell, D., Swingler, R., Traynor, B.J., 2010. Amyotrophic lateral sclerosis, physical exercise, trauma and sports: results of a population-based pilot case-control study. *Amyotroph. Lateral Scler.* 11, 289–292.
- Belli, S., Vanacore, N., 2005. Proportionate mortality of Italian soccer players: is amyotrophic lateral sclerosis an occupational disease? *Eur. J. Epidemiol.* 20, 237–242.
- Bendotti, C., Carri, M.T., 2004. Lessons from models of SOD1-linked familial ALS. *Trends Mol. Med.* 10, 393–400.
- Boillee, S., Vande Velde, C., Cleveland, D.W., 2006. ALS: a disease of motor neurons and their nonneuronal neighbors. *Neuron* 52, 39–59.
- Borgia, D., Malena, A., Spinazzi, M., Desbats, M.A., Salviati, L., Russell, A.P., Miotto, G., Tosatto, L., Pegoraro, E., Soraru, G., Pennuto, M., Vergani, L., 2017. Increased mitophagy in the skeletal muscle of spinal and bulbar muscular atrophy patients. *Hum. Mol. Genet.* 26, 1087–1103.
- Bottner, M., Kriegstein, K., Unsicker, K., 2000. The transforming growth factor-beta: structure, signaling, and roles in nervous system development and functions. *J. Neurochem.* 75, 2227–2240.
- Braga, M., Bhasin, S., Jasuja, R., Pervin, S., Singh, R., 2012. Testosterone inhibits transforming growth factor-beta signaling during myogenic differentiation and proliferation of mouse satellite cells: potential role of follistatin in mediating testosterone action. *Mol. Cell Endocrinol.* 350, 39–52.
- Brooks, B.R., Miller, R.G., Swash, M., Munsat, T.L., 2000. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. *Amyotroph. Lateral Scler. Other Mot. Neuron Disord* 1, 293–299.
- Burks, T.N., Andres-Mateos, E., Marx, R., Mejias, R., Van Erp, C., Simmers, J.L., Walston, J.D., Ward, C.W., Cohn, R.D., 2011. Losartan restores skeletal muscle remodeling and protects against disuse atrophy in sarcopenia. *Sci. Transl. Med.* 3, 82ra37.
- Burks, T.N., Cohn, R.D., 2011. Role of TGF-beta signaling in inherited and acquired myopathies. *Skelet. Muscle* 1, 19.
- Calvo, A.C., Manzano, R., Atencia-Cibreiro, G., Olivan, S., Munoz, M.J., Zaragoza, P., Cordero-Vazquez, P., Esteban-Perez, J., Garcia-Redondo, A., Osta, R., 2012. Genetic biomarkers for ALS disease in transgenic SOD1(G93A) mice. *PLoS One* 7, e23632.
- Cao, Q., Mak, K.M., Lieber, C.S., 2002. DLPC decreases TGF-beta1-induced collagen mRNA by inhibiting p38 MAPK in hepatic stellate cells. *Am. J. Physiol. Gastrointest. Liver Physiol.* 283, G1051–G1061.
- Chio, A., Benzi, G., Dossena, M., Mutani, R., Mora, G., 2005. Severely increased risk of amyotrophic lateral sclerosis among Italian professional football players. *Brain* 128 (Pt 3), 472–476.
- Cohn, R.D., van Erp, C., Habashi, J.P., Soleimani, A.A., Klein, E.C., Lisi, M.T., Gamradt, M., ap Rhys, C.M., Holm, T.M., Loeys, B.L., Ramirez, F., Judge, D.P., Ward, C.W., Dietz, H.C., 2007. Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. *Nat. Med.* 13, 204–210.
- Corti, S., Donadoni, C., Ronchi, D., Bordini, A., Fortunato, F., Santoro, D., Del Bo, R., Lucchini, V., Crugnola, V., Papadimitriou, D., Salani, S., Moggio, M., Bresolin, N., Comi, G.P., 2009. Amyotrophic lateral sclerosis linked to a novel SOD1 mutation with muscle mitochondrial dysfunction. *J. Neurol. Sci.* 276, 170–174.
- Crippa, V., Boncoraglio, A., Galbiati, M., Aggarwal, T., Rusmini, P., Giorgetti, E., Cristofani, R., Carra, S., Pennuto, M., Poletti, A., 2013. Differential autophagy power in the spinal cord and muscle of transgenic ALS mice. *Front Cell Neurosci* 7, 234.
- D'Arrigo, A., Colavito, D., Pena-Altamira, E., Fabris, M., Dam, M., Contestabile, A., Leon, A., 2010. Transcriptional profiling in the lumbar spinal cord of a mouse model of amyotrophic lateral sclerosis: a role for wild-type superoxide dismutase 1 in sporadic disease? *J. Mol. Neurosci.* 41, 404–415.

- Dobrowolny, G., Aucello, M., Rizzuto, E., Beccafico, S., Mammucari, C., Boncompagni, S., Belia, S., Wannenes, F., Nicoletti, C., Del Prete, Z., Rosenthal, N., Molinaro, M., Protasi, F., Fano, G., Musaro, A., 2008. Skeletal muscle is a primary target of SOD1G93A-mediated toxicity. *Cell Metab.* 8, 425–436.
- Dooley, S., Delvoux, B., Lahme, B., Mangasser-Stephan, K., Gressner, A.M., 2000. Modulation of transforming growth factor beta response and signaling during transdifferentiation of rat hepatic stellate cells to myofibroblasts. *Hepatology* 31, 1094–1106.
- Endo, F., Komine, O., Fujimori-Tonou, N., Katsuno, M., Jin, S., Watanabe, S., Sobue, G., Dezawa, M., Wyss-Coray, T., Yamanaka, K., 2015. Astrocyte-derived TGF-beta1 accelerates disease progression in ALS mice by interfering with the neuroprotective functions of microglia and T cells. *Cell Rep.* 11, 592–604.
- Fischer, L.R., Culver, D.G., Tennant, P., Davis, A.A., Wang, M., Castellano-Sanchez, A., Khan, J., Polak, M.A., Glass, J.D., 2004. Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. *Exp. Neurol.* 185, 232–240.
- Fragiadaki, M., Ikeda, T., Witherden, A., Mason, R.M., Abraham, D., Bou-Gharios, G., 2011. High doses of TGF-beta potently suppress type I collagen via the transcription factor CUX1. *Mol. Biol. Cell* 22, 1836–1844.
- Frey, D., Schneider, C., Xu, L., Borg, J., Spooren, W., Caroni, P., 2000. Early and selective loss of neuromuscular synapse subtypes with low sprouting competence in motoneuron diseases. *J. Neurosci.* 20, 2534–2542.
- Galbiati, M., Crippa, V., Rusmini, P., Cristofani, R., Cicardi, M.E., Giorgetti, E., Onesto, E., Messi, E., Poletti, A., 2014. ALS-related misfolded protein management in motor neurons and muscle cells. *Neurochem. Int.* 79, 70–78.
- Galbiati, M., Onesto, E., Zito, A., Crippa, V., Rusmini, P., Mariotti, R., Bentivoglio, M., Bendotti, C., Poletti, A., 2012. The anabolic/androgenic steroid nandrolone exacerbates gene expression modifications induced by mutant SOD1 in muscles of mice models of amyotrophic lateral sclerosis. *Pharmacol. Res.* 65, 221–230.
- Gonzalez, D., Contreras, O., Rebollo, D.L., Espinoza, J.P., van Zundert, B., Brandan, E., 2017. ALS skeletal muscle shows enhanced TGF-beta signaling, fibrosis and induction of fibro/adipogenic progenitor markers. *PLoS One* 12, e0177649.
- Gonzalez de Aguilar, J.L., Niederhauser-Wiederkehr, C., Halter, B., De Tapia, M., Di Scala, F., Demougin, P., Dupuis, L., Primig, M., Meininger, V., Loeffler, J.P., 2008. Gene profiling of skeletal muscle in an amyotrophic lateral sclerosis mouse model. *Physiol. Genomics* 32, 207–218.
- Groeneveld, G.J., Van Muiswinkel, F.L., Sturkenboom, J.M., Wokke, J.H., Bar, P.R., Van den Berg, L.H., 2004. Ovariectomy and 17beta-estradiol modulate disease progression of a mouse model of ALS. *Brain Res.* 1021, 128–131.
- Haverkamp, L.J., Appel, V., Appel, S.H., 1995. Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. *Brain* 118 (Pt 3), 707–719.
- Heiman-Patterson, T.D., Deitch, J.S., Blankenhorn, E.P., Erwin, K.L., Perreault, M.J., Alexander, B.K., Byers, N., Toman, I., Alexander, G.M., 2005. Background and gender effects on survival in the TgN(SOD1-G93A)1Gur mouse model of ALS. *J. Neurol. Sci.* 236, 1–7.
- Hocevar, B.A., Brown, T.L., Howe, P.H., 1999. TGF-beta induces fibronectin synthesis through a c-Jun N-terminal kinase-dependent, Smad4-independent pathway. *EMBO J.* 18, 1345–1356.
- Houji, K., Kobayashi, T., Kato, S., Mochio, S., Inoue, K., 2002. Increased plasma TGF-beta1 in patients with amyotrophic lateral sclerosis. *Acta Neurol. Scand.* 106, 299–301.
- Iida, A., Takahashi, A., Kubo, M., Saito, S., Hosono, N., Ohnishi, Y., Kiyotani, K., Mushiroda, T., Nakajima, M., Ozaki, K., Tanaka, T., Tsunoda, T., Oshima, S., Sano, M., Kamei, T., Tokuda, T., Aoki, M., Hasegawa, K., Mizoguchi, K., Morita, M., Takahashi, Y., Katsuno, M., Atsuta, N., Watanabe, H., Tanaka, F., Kaji, R., Nakano, I., Kamatani, N., Tsuji, S., Sobue, G., Nakamura, Y., Ikegawa, S., 2011. A functional variant in ZNF512B is associated with susceptibility to amyotrophic lateral sclerosis in Japanese. *Hum. Mol. Genet.* 20, 3684–3692.
- Ilzecka, J., Stelmasiak, Z., Dobosz, B., 2002. Transforming growth factor-Beta 1 (tgf-Beta 1) in patients with amyotrophic lateral sclerosis. *Cytokine* 20, 239–243.
- Jensen, L., Jorgensen, L.H., Bech, R.D., Frandsen, U., Schroder, H.D., 2016. Skeletal muscle remodelling as a function of disease progression in amyotrophic lateral sclerosis. *Biomed. Res. Int.* 2016, 5930621.
- Kennel, P.F., Finiels, F., Revah, F., Mallet, J., 1996. Neuromuscular function impairment is not caused by motor neurone loss in FALS mice: an electromyographic study. *Neuroreport* 7, 1427–1431.
- Kirby, J., Ning, K., Ferraiuolo, L., Heath, P.R., Ismail, A., Kuo, S.W., Valori, C.F., Cox, L., Sharrack, B., Wharton, S.B., Ince, P.G., Shaw, P.J., Azzouz, M., 2011. Phosphatase and tensin homologue/protein kinase B pathway linked to motor neuron survival in human superoxide dismutase 1-related amyotrophic lateral sclerosis. *Brain* 134 (Pt 2), 506–517.
- Kollias, H.D., McDermott, J.C., 2008. Transforming growth factor-beta and myostatin signaling in skeletal muscle. *J. Appl. Physiol.* (1985) 104, 579–587.
- Kriegstein, K., Strelau, J., Schober, A., Sullivan, A., Unsicker, K., 2002. TGF-beta and the regulation of neuron survival and death. *J. Physiol. Paris* 96, 25–30.
- Kurisaki, A., Kose, S., Yoneda, Y., Heldin, C.H., Moustakas, A., 2001. Transforming growth factor-beta induces nuclear import of Smad3 in an importin-beta1 and Ran-dependent manner. *Mol. Biol. Cell* 12, 1079–1091.
- La Spada, A.R., Wilson, E.M., Lubahn, D.B., Harding, A.E., Fischbeck, K.H., 1991. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. *Nature* 352, 77–79.
- Labbe, E., Silvestri, C., Hoodless, P.A., Wrana, J.L., Attisano, L., 1998. Smad2 and Smad3 positively and negatively regulate TGF beta-dependent transcription through the forkhead DNA-binding protein FAST2. *Mol. Cell* 2, 109–120.
- Levine, T.P., Daniels, R.D., Gatta, A.T., Wong, L.H., Hayes, M.J., 2013. The product of C9orf72, a gene strongly implicated in neurodegeneration, is structurally related to DENN Rab-GEFs. *Bioinformatics* 29, 499–503.
- Li, Y., Foster, W., Deasy, B.M., Chan, Y., Prisk, V., Tang, Y., Cummins, J., Huard, J., 2004. Transforming growth factor-beta1 induces the differentiation of myogenic cells into fibrotic cells in injured skeletal muscle: a key event in muscle fibrogenesis. *Am. J. Pathol.* 164, 1007–1019.
- Lieberman, A.P., Yu, Z., Murray, S., Peralta, R., Low, A., Guo, S., Yu, X.X., Cortes, C.J., Bennett, C.F., Monia, B.P., La Spada, A.R., Hung, G., 2014. Peripheral androgen receptor gene suppression rescues disease in mouse models of spinal and bulbar muscular atrophy. *Cell Rep.* 7, 774–784.
- Liu, D., Black, B.L., Derynck, R., 2001. TGF-beta inhibits muscle differentiation through functional repression of myogenic transcription factors by Smad3. *Genes Dev.* 15, 2950–2966.
- Logroscino, G., Traynor, B.J., Hardiman, O., Chio, A., Mitchell, D., Swigler, R.J., Millul, A., Benn, E., Beghi, E., 2010. Incidence of amyotrophic lateral sclerosis in Europe. *J. Neurol. Neurosurg. Psychiatry* 81, 385–390.
- Manjaly, Z.R., Scott, K.M., Abhinav, K., Wijesekera, L., Ganesalingam, J., Goldstein, L.H., Janssen, A., Dougherty, A., Willey, E., Stanton, B.R., Turner, M.R., Ampong, M.A., Sakel, M., Orrell, R.W., Howard, R., Shaw, C.E., Leigh, P.N., Al-Chalabi, A., 2010. The sex ratio in amyotrophic lateral sclerosis: a population based study. *Amyotroph. Lateral Scler.* 11, 439–442.
- Massague, J., Cheifetz, S., Endo, T., Nadal-Ginard, B., 1986. Type beta transforming growth factor is an inhibitor of myogenic differentiation. *Proc. Natl. Acad. Sci. U. S. A.* 83, 8206–8210.
- McLennan, I.S., Koishi, K., 2002. The transforming growth factor-betas: multifaceted regulators of the development and maintenance of skeletal muscles, motoneurons and Schwann cells. *Int. J. Dev. Biol.* 46, 559–567.
- Miller, T.M., Kim, S.H., Yamanaka, K., Hester, M., Umaphathi, P., Arnsen, H., Rizo, L., Mendell, J.R., Gage, F.H., Cleveland, D.W., Kaspar, B.K., 2006. Gene transfer demonstrates that muscle is not a primary target for non-cell-autonomous toxicity in familial amyotrophic lateral sclerosis. *Proc. Natl. Acad. Sci. U. S. A.* 103, 19546–19551.
- Nakamura, M., Ito, H., Wate, R., Nakano, S., Hirano, A., Kusaka, H., 2008. Phosphorylated Smad2/3 immunoreactivity in sporadic and familial amyotrophic lateral sclerosis and its mouse model. *Acta Neuropathol.* 115, 327–334.
- Olson, E.N., Sternberg, E., Hu, J.S., Spizz, G., Wilcox, C., 1986. Regulation of myogenic differentiation by type beta transforming growth factor. *J. Cell Biol.* 103, 1799–1805.
- Onesto, E., Rusmini, P., Crippa, V., Ferri, N., Zito, A., Galbiati, M., Poletti, A., 2011. Muscle cells and motoneurons differentially remove mutant SOD1 causing familial amyotrophic lateral sclerosis. *J. Neurochem.* 118, 266–280.
- Pasinelli, P., Brown, R.H., 2006. Molecular biology of amyotrophic lateral sclerosis: insights from genetics. *Nat. Rev. Neurosci.* 7, 710–723.
- Peters, S., Zitzelsperger, E., Kuespert, S., Iberl, S., Heydn, R., Johannessen, S., Petri, S., Aigner, L., Thal, D.R., Hermann, A., Weishaupt, J.H., Bruun, T.H., Bogdahn, U., 2017. The TGF-beta system As a potential pathogenic player in disease modulation of amyotrophic lateral sclerosis. *Front. Neurol.* 8, 669.
- Phatnani, H.P., Guarnieri, P., Friedman, B.A., Carrasco, M.A., Muratet, M., O'Keefe, S., Nwazke, C., Pauli-Behn, F., Newberry, K.M., Meadows, S.K., Tapia, J.C., Myers, R.M., Maniatis, T., 2013. Intricate interplay between astrocytes and motor neurons in ALS. *Proc. Natl. Acad. Sci. U. S. A.* 110, E756–E765.
- Piazza, O., Siren, A.L., Ehrenreich, H., 2004. Soccer, neurotrauma and amyotrophic lateral sclerosis: is there a connection? *Curr. Med. Res. Opin.* 20, 505–508.
- Pradat, P.F., Dubourg, O., de Tapia, M., di Scala, F., Dupuis, L., Lenglet, T., Bruneteau, G., Salachas, F., Lacomblez, L., Corvol, J.C., Demougin, P., Primig, M., Meininger, V., Loeffler, J.P., Gonzalez de Aguilar, J.L., 2012. Muscle gene expression is a marker of amyotrophic lateral sclerosis severity. *Neurodegener. Dis.* 9, 38–52.
- Qi, Y., Yin, X., Wang, S., Jiang, H., Wang, X., Ren, M., Su, X.P., Lei, S., Feng, H., 2015. PGC-1alpha silencing compounds the perturbation of mitochondrial function caused by mutant SOD1 in skeletal muscle of ALS mouse model. *Front. Aging Neurosci.* 7, 204.
- Rudnicki, S.A., 1999. Estrogen replacement therapy in women with amyotrophic lateral sclerosis. *J. Neurol. Sci.* 169, 126–127.
- Rusmini, P., Polanco, M.J., Cristofani, R., Cicardi, M.E., Meroni, M., Galbiati, M., Piccolella, M., Messi, E., Giorgetti, E., Lieberman, A.P., Milioto, C., Rocchi, A., Aggarwal, T., Pennuto, M., Crippa, V., Poletti, A., 2015. Aberrant autophagic response in the muscle of A knock-in mouse model of spinal and bulbar muscular atrophy. *Sci. Rep.* 5, 15174.
- Saris, C.G., Groen, E.J., van Vught, P.W., van Es, M.A., Blauw, H.M., Veldink, J.H., van den Berg, L.H., 2013. Gene expression profile of SOD1-G93A mouse spinal cord, blood and muscle. *Amyotroph. Lateral Scler. Frontotemporal Degener.* 14, 190–198.
- Sato, M., Shegogue, D., Hatamochi, A., Yamazaki, S., Trojanowska, M., 2004. Lyso-phosphatidic acid inhibits TGF-beta-mediated stimulation of type I collagen mRNA stability via an ERK-dependent pathway in dermal fibroblasts. *Matrix Biol.* 23, 353–361.
- Shi, Y., Massague, J., 2003. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. *Cell* 113, 685–700.
- Si, Y., Kim, S., Cui, X., Zheng, L., Oh, S.J., Anderson, T., AlSharabati, M., Kazamel, M., Volpicelli-Daley, L., Bammann, M.M., Yu, S., King, P.H., 2015. Transforming growth factor beta (TGF-beta) is a muscle biomarker of disease progression in ALS and correlates with Smad expression. *PLoS One* 10, e0138425.
- Singh, R., Bhasin, S., Braga, M., Artaza, J.N., Pervin, S., Taylor, W.E., Krishnan, V., Sinha, S.K., Rajavashisth, T.B., Jasuja, R., 2009. Regulation of myogenic

- differentiation by androgens: cross talk between androgen receptor/beta-catenin and follistatin/transforming growth factor-beta signaling pathways. *Endocrinology* 150, 1259–1268.
- Tesseur, I., Zou, K., Esposito, L., Bard, F., Berber, E., Can, J.V., Lin, A.H., Crews, L., Tremblay, P., Mathews, P., Mucke, L., Masliah, E., Wyss-Coray, T., 2006. Deficiency in neuronal TGF-beta signaling promotes neurodegeneration and Alzheimer's pathology. *J. Clin. Invest.* 116, 3060–3069.
- Trappe, T., 2009. Influence of aging and long-term unloading on the structure and function of human skeletal muscle. *Appl. Physiol. Nutr. Metab.* 34, 459–464.
- Veldink, J.H., Bar, P.R., Joosten, E.A., Otten, M., Wokke, J.H., van den Berg, L.H., 2003. Sexual differences in onset of disease and response to exercise in a transgenic model of ALS. *Neuromuscul. Disord.* 13, 737–743.
- von Maltzahn, J., Jones, A.E., Parks, R.J., Rudnicki, M.A., 2013. Pax7 is critical for the normal function of satellite cells in adult skeletal muscle. *Proc. Natl. Acad. Sci. U. S. A.* 110, 16474–16479.
- Wong, M., Martin, L.J., 2010. Skeletal muscle-restricted expression of human SOD1 causes motor neuron degeneration in transgenic mice. *Hum. Mol. Genet.* 19, 2284–2302.
- Yu, Z., Dadgar, N., Albertelli, M., Gruis, K., Jordan, C., Robins, D.M., Lieberman, A.P., 2006a. Androgen-dependent pathology demonstrates myopathic contribution to the Kennedy disease phenotype in a mouse knock-in model. *J. Clin. Invest.* 116, 2663–2672.
- Yu, Z., Dadgar, N., Albertelli, M., Scheller, A., Albin, R.L., Robins, D.M., Lieberman, A.P., 2006b. Abnormalities of germ cell maturation and sertoli cell cytoskeleton in androgen receptor 113 CAG knock-in mice reveal toxic effects of the mutant protein. *Am. J. Pathol.* 168, 195–204.
- Zhang, J., Ito, H., Wate, R., Ohnishi, S., Nakano, S., Kusaka, H., 2006. Altered distributions of nucleocytoplasmic transport-related proteins in the spinal cord of a mouse model of amyotrophic lateral sclerosis. *Acta Neuropathol.* 112, 673–680.